SII on track to meet need for 30-40 cr vaccine doses by July, says Adar Poonawalla after Modi visit
Poonawalla also said the SII is in the process of applying for an emergency usage licence, and that he has discussed an implementation plan with Prime Minister Modi during his visit to its Pune facility on Saturday
The erroneous trial results of the AstraZeneca-Oxford vaccine candidate will not impact the manufacturing or delivery schedule of the 'Covieshield', the Indian version of the experimental vaccine, Adar Poonawalla, the CEO of Pune-based Serum Institute of India which is manufacturing the vaccine in India reiterated on Saturday.
Poonawalla's remarks came days after AstraZeneca and Oxford University acknowledged a manufacturing error that has raised questions about preliminary results of their experimental COVID-19 vaccine. Earlier on Saturday, Prime Minister Narendra Modi also visited the vaccine major's Pune facility.
Poonawala also saidthat the SII is working towards meeting the need for 30 to 40 crore (300 to 400 million) doses of vaccine that the Ministry of Health Affairs may require by July.
"As of now, we don't have anything in writing with the government of India on how many doses they will purchase but the indication is that it would be 300-400 million doses by July 2021," he told reporters.
The SII, he informed, is in the process of applying for an emergency usage license in the next two weeks.
Poonawalla also said he discussed an implementation plan with Modi after the Covieshield is granted an emergency usage authorisation.
"This," however, he said, "will happen after the company submits its efficacy trials data with the government and provided the trials in the UK go well."
"It will be a decision of the health ministry," he added.
Adar Poonawalla Speaks About COVISHIELD - Live https://t.co/nN52Be0xIi
— SerumInstituteIndia (@SerumInstIndia) November 28, 2020
Giving a status update on the other vaccine candidates which are under various stages of development and trials at the SII, Poonawala said that the trials of Covieshield are on time, whereas the Covax is around two months behind it.
The phase one trials of a third vaccine candidate, Codagenix are expected to start in the UK in December, he informed.
Poonawalla also said that the SII's priority will be first distributing the Covieshield vaccine in India and Covax countries, which primarily includes Africa.
The UK and European markets are taken care of by Astrazeneca and Oxford University, he added.
Besides SII, Modi on Saturday also visited the pharma major Zydus Cadila's plant in Gujarat and then flew to Hyderabad where he visited Bharat BioTech which is working on the indigenous Covaxin candidate.
Poonawalla said that he briefed Modi about the work being carried out at SII and on the progress of the vaccine.
"Had a good interaction with the team at Serum Institute of India. They shared details about their progress so far on how they plan to further ramp up vaccine manufacturing. Also took a look at their manufacturing facility," Modi tweeted after his SII visit.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
Doses of the vaccine, Covishield, will initially be shipped to 60 consignee points and will then be distributed to various vaccination centres across India
COVID-19 vaccination: First Covishield consignment leaves Serum Institute, to be sent to 13 locations
The vaccines will be flown from Pune in eight commercial flights, including two cargo flights, a source told PTI
Centre buys 11 mn doses of Covishield; Narendra Modi calls COVID-19 vaccines made in India 'most cost-effective'
The country also recorded the lowest daily spike in cases and deaths in nearly eight months, the Union health ministry said on Monday